STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
27
13F, latest reported quarter
What the filings say about PED
Insiders, 180 days
+$1.8M net bought
2 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$129.4K
3 notices
Pedevco insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PEDEVCO CORP insiders bought a net $1.8M of stock across 83 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
19 earlier Form 4 trades (code P or S) here by this insider (19 buys), the last on Mar 30, 2023.
-6.3% median (-5.3% mean) 90-day return after 17 previous buys.
The trade is 3.6% of the 4,137,543 shares held after it.
No other insider bought within 30 days.
27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider KUKES SIMON G bought about $1.9M of PED on Oct 8, 2026, the largest insider purchase at the company on our record; 27 funds added in the latest 13F quarter.
13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Nov 24, 2025.
The trade is 34.5% of the 54,428 shares held after it.
No other insider sold within 30 days.
27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive VP Clark Moore sold about $275.8K of PED on Jun 30, 2026, the largest insider sale at the company on our record; 27 funds added in the latest 13F quarter.
83 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
PED planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Clark Moore
Filed 2026-08-19
$15.1K
Clark Moore
Filed 2026-08-18
$66.1K
Clark Moore
Filed 2026-08-17
$48.2K
Clark Moore
Filed 2026-06-30
$275.8K
PED mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$99.4K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$61.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$3.7K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$26.4K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Value ETF
$244.7K position · as of 2026-05-31
0.0%
Nuveen Small Cap Blend Index Fund
$31.5K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Dr. Simon Kukes
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.0M
$1.0M
$748.3K
-50%
n/a
2024
$367.1K
$383.7K
$630.5K
-30%
n/a
2023
$436.0K
$181.0K
$646.2K
-30%
n/a
2022
$468.0K
$483.5K
$636.8K
+4%
n/a
2021
$417.0K
$91.8K
$548.9K
-30%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.8M bought by insiders over 180 days, 27 funds added last quarter, $129.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$116.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PED
FY Dec 2025
$45.8M
FY Dec 2024
$39.6M
FY Dec 2023
n/a
FY Dec 2022
$30.8M
FY Dec 2021
$15.9M
Jun 2026
$46.1M
Mar 2026
$40.2M
Dec 2025
$23.1M
Sep 2025
$7.0M
Jun 2025
$7.0M
Mar 2025
$8.7M
Dec 2024
$10.6M
Sep 2024
$9.1M
At each fiscal year end
Single quarter
Net margin, TTM
-14.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PED
FY Dec 2025
-22.6%
FY Dec 2024
+31.1%
FY Dec 2023
n/a
FY Dec 2022
+9.2%
FY Dec 2021
-8.2%
Jun 2026
+37.9%
Mar 2026
-63.7%
Dec 2025
-36.8%
Sep 2025
-4.7%
Jun 2025
-24.0%
Mar 2025
+1.6%
Dec 2024
+56.0%
Sep 2024
+32.2%
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM PED
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2019-12-31 (79 months older than the period end); equity 2026-06-30
Debt to equity PED
FY Dec 2025
0.00x
FY Dec 2024
0.00x
FY Dec 2023
0.00x
FY Dec 2022
0.00x
FY Dec 2021
0.00x
Jun 2026
0.00x
Mar 2026
0.00x
Dec 2025
0.00x
Sep 2025
0.00x
Jun 2025
0.00x
Mar 2025
0.00x
Dec 2024
0.00x
Sep 2024
0.00x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt PED
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-10.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PED
FY Dec 2025
-6.4%
FY Dec 2024
+11.3%
FY Dec 2023
+1.7%
FY Dec 2022
+3.0%
FY Dec 2021
-1.6%
Jun 2026
-10.8%
Mar 2026
-24.2%
Dec 2025
-6.4%
Sep 2025
+3.7%
Jun 2025
+6.7%
Mar 2025
+10.8%
Dec 2024
+11.3%
Sep 2024
+3.6%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-6.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PED
FY Dec 2025
-4.1%
FY Dec 2024
+9.8%
FY Dec 2023
+1.4%
FY Dec 2022
+2.7%
FY Dec 2021
-1.5%
Jun 2026
-6.8%
Mar 2026
-14.0%
Dec 2025
-4.1%
Sep 2025
+3.2%
Jun 2025
+5.9%
Mar 2025
+8.8%
Dec 2024
+9.8%
Sep 2024
+3.4%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital PED
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PED
FY Dec 2025
-3.6%
FY Dec 2024
+4.2%
FY Dec 2023
+1.2%
FY Dec 2022
+2.7%
FY Dec 2021
-2.2%
Jun 2026
+7.5%
Mar 2026
-0.6%
Dec 2025
-3.6%
Sep 2025
-3.7%
Jun 2025
-0.5%
Mar 2025
+3.7%
Dec 2024
+4.2%
Sep 2024
+3.1%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PED
FY Dec 2025
n/a
FY Dec 2024
5.64x
FY Dec 2023
770.00x
FY Dec 2022
733.33x
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
4.92x
Jun 2025
5.50x
Mar 2025
5.04x
Dec 2024
5.64x
Sep 2024
470.00x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$195.6M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term debt only, 2019-12-31 (79 months older than the period end), minus cash 2026-06-30
Enterprise value PED
FY Dec 2025
$1.1B
FY Dec 2024
$1.4B
FY Dec 2023
$1.3B
FY Dec 2022
$1.9B
FY Dec 2021
$1.8B
Jun 2026
$168.2M
Mar 2026
$205.1M
Dec 2025
$1.1B
Sep 2025
$1.1B
Jun 2025
$1.2B
Mar 2025
$1.3B
Dec 2024
$1.4B
Sep 2024
$1.7B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield PED
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PED
FY Dec 2025
n/a
FY Dec 2024
0.00x
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
0.00x
Jun 2025
0.00x
Mar 2025
0.00x
Dec 2024
0.00x
Sep 2024
1.57x
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
PED ranks highest on financial health (99th percentile) and insider conviction (81st), and lowest on institutional and government (14th), among Energy peers.
Profitability
33
Inputs
Return on equity-10.8% · 21 pct, sector of 109
Return on assets-6.8% · 23 pct, sector of 129
Return on invested capitalpre-tax loss, no effective tax rate to apply
Return on capital employed+7.5% · 55 pct, sector of 110
Financial health
100
Inputs
Debt to equity0.00x · 100 pct, sector of 111
Cash flow to debtno debt to cover
Growth
75
Inputs
Revenue growth, YoY+15.7% · 75 pct, sector of 141
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
81
Inputs
Net Form 4 buying (codes P and S), 180d$1.8M · 90 pct, sector of 95
Insider buyers, 180d2 · 71 pct, sector of 95
Institutional and government
14
Inputs
Funds adding, latest quarter27 · 14 pct, sector of 145
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
32
Inputs
Short interest, % of float+4.5% · 51 pct, sector of 167
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-K+24.4% · 14 pct, sector of 120
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PED filings, in plain words
Are Pedevco insiders buying or selling PED?
In the 180 days to 2026-10-28, Pedevco insiders were net buyers, a net $1.8M: $2.2M of purchases and $405.2K of sales reported on Form 4, by 2 buyers and 1 seller.
Are there planned insider sales of PED?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $129.4K of stock; the latest, by Clark Moore, was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-28, Pedevco insiders were net buyers of PED, a net $1.8M across purchases and sales reported on Form 4 by 2 buyers and 1 seller. Most of that figure, $1.9M, came from a holder of 10% or more rather than an officer or director. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $129.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.